.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free and overall survival, triggering FDA commendation as well as a brand new therapy option for clients.